Vaccine Research at Pitt

The Pittsburgh Vaccine Trials Unit at the University of Pittsburgh connects research study participants with local vaccine clinical trials. See below to learn how you can help.

Pittsburgh Vaccine Trials Unit

The Pittsburgh Vaccine Trials Unit is open to people of all ages, races, ethnicities and genders. Including diverse populations in clinicals trials is important to ensure that everyone is represented in the research and to help researchers find out if vaccines will work and be safe for everyone. By joining the Pittsburgh Vaccine Trials Unit, you can learn more about vaccine clinical trials in Pittsburgh and you may be asked to participate. Participation in research is always voluntary.

Interested in signing up for the Pittsburgh Vaccine Trials Unit to learn more about vaccine research and COVID-19 clinical trials? Contact the study team directly at VTEU@chp.edu or 412-692-7382 or click the button below to sign up online.

Investigator photo

Judy Martin, MD
Principal Investigator

Pediatric Moderna Study

A study to evaluate safety and effectiveness of mRNA-1273 vaccine in healthy children between 6 months of age and less than 12 years of age.

VIEW MORE INFORMATION
Investigator photo

Judy Martin, MD
Principal Investigator

Adult Booster Dose Study

This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of a delayed (>12 weeks) vaccine boost on a range of Emergency Use Authorization dosing (EUA)-dosed COVID-19 vaccines.

VIEW MORE INFORMATION
Investigator photo

Judy Martin, MD
Principal Investigator

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)

The study will enroll up to 60,000 participants in order to evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.

VIEW MORE INFORMATION
Investigator photo

Sharon A. Riddler, MD
Principal Investigator

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.

VIEW MORE INFORMATION
Investigator photo

Judy Martin, MD
Principal Investigator

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 SARS-COV-2 vaccine in adults 18 years of age or older.

VIEW MORE INFORMATION

About the Clinical and Translational Science Institute (CTSI)

The University of Pittsburgh’s CTSI transforms scientific research and clinical discoveries into modern medical techniques that improve lives. From bench to bedside and everything in between, CTSI creates, supports and encourages opportunities that better the human condition. An integral part of the National Institutes of Health (NIH) nationwide network, CTSI provides the support necessary to bridge the gap between innovative approaches to research and effective clinical and public health practice and policy.

Visit the CTSI website to learn more.

About Pitt+Me

Pitt+Me is a program that shares information with the public about research study opportunities at the University of Pittsburgh and UPMC. Pitt+Me is open to children and adults of all ages, healthy or sick, and features hundreds of research studies on a variety of physical and mental health topics.

If you’re interested in COVID-19 research studies for adults and children or learning more about research opportunities at the University of Pittsburgh, enroll in Pitt+Me online or contact us at PittPlusMe@pitt.edu or 1-866-438-8230.